UMIN-CTR History

Name:  UMIN ID:


Unique ID issued by UMIN UMIN000001331
Receipt number R000001613
Scientific Title Phase II study of neoadjuvant Letrozole combined with low dose metronomic Cyclophosphamide for postmenopausal women with Endocrine-responsive Breast Cancer (JBCRG-07)
Date of disclosure of the study information 2008/08/22
Last modified on 2021/08/18 09:41:00

No. Disposal Last modified on Item of update
1 Insert 2008/08/21 23:33:44
2 Update 2008/12/16 14:27:15 Email1


3 Update 2009/08/21 11:19:37 Organization
Organization
Institute
Organization
Organization1
4 Update 2009/10/29 19:55:07 Recruitment status
5 Update 2011/02/21 11:45:24 Recruitment status
6 Update 2011/08/31 14:19:14 Post marketing survey by drug manufacture etc., specified by Japanese law.
Tel1
7 Update 2011/11/15 15:50:40 Publication of results
Other related information
Other related information
8 Update 2014/02/21 13:52:43 Email
Institutions
9 Update 2014/08/26 09:27:11 Address
Address
TEL
Address
Address
TEL
Address1
Tel1
10 Update 2014/09/26 10:23:40 Last follow-up date
11 Update 2015/08/24 10:42:25 Recruitment status
12 Update 2016/07/06 09:38:20 Name of primary person or sponsor
Organization
13 Update 2018/08/24 10:02:54 UMIN ID1
UMIN ID2
14 Update 2019/11/21 16:47:57 1st name of lead principal investigator
Last name of lead principal investigator
1st name of lead principal investigator
Last name of lead principal investigator
Zip code
Address

Last name of contact person

Last name of contact person
Organization
Zip code
Address
Homepage URL
Organization
Institute
Organization
Organization1
Organization
Organization
Address
Address
Tel
Email
15 Update 2019/11/21 16:52:26 Date of IRB
Anticipated trial start date
16 Update 2021/08/18 09:41:00 URL releasing protocol
Publication of results
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results
Results date posted
Date of the first journal publication of results
Baseline Characteristics
Baseline Characteristics
Participant flow
Participant flow
Adverse events
Adverse events
Outcome measures
Outcome measures